Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
1
14%
Ph phase_3
3
43%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

NCT05255094
completedphase_3

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

NCT05260411
completedphase_1

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

NCT04169386
completedphase_3

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

NCT05255458
completedphase_2

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

NCT03933293
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05255094Phase 3

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Completed
NCT05260411Phase 3

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Completed
NCT04169386Phase 1

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Completed
NCT05255458Phase 3

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Completed
NCT03933293Phase 2

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

Completed
NCT04173793Phase 2

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Completed
NCT04358432Phase 2

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7